Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here